Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis*

Parasite Immunology - Tập 24 Số 6 - Trang 295-301 - 2002
Uwe Ritter1, Heinrich Körner1
1Nikolaus-Fiebiger Zentrum für Molekulare Medizin, University of Erlangen-Nürnberg, Erlangen, Germany.

Tóm tắt

SummaryHuman leishmaniasis is caused by protozoan Leishmania (L.) parasites and comprises a heterogeneous group of clinical appearances ranging from visceral to cutaneous leishmaniasis. In the New World, L. mexicana mediates American cutaneous leishmaniasis, one of the most common forms of this disease. Two different disease progressions can be observed: (i) self‐healing localized cutaneous leishmaniasis (LCL) and (ii) progressive diffuse cutaneous leishmaniasis (DCL). These different forms are associated with a T helper 1 (Th1) or Th2 response, respectively, and are additionally characterized by opposing dermal chemokine profiles. Lesions of LCL show high expression of CCL2/MCP‐1, CXCL9/MIG, CXCL10/IP‐10 and only low amounts of CCL3/MIP‐1α. In contrast, lesions of chronic DCL are dominated by the expression of CCL3/MIP‐1α. This finding implies that CCL2/MCP‐1 contributes to the healing process. Indeed, CCL2/MCP‐1 induces leishmanicidal activities in human monocytes in contrast to CCL3/MIP‐1α. This effect is enhanced by interferon‐γ and abrogated by interleukin‐4. In the murine model of leishmaniasis, the impact of CCL2/MCP‐1 is well documented. Normally resistant mice become susceptible for Leishmania infections if CCR2, the receptor for CCL2/MCP‐1, is knocked out. Based on this evidence, we propose that tissue specific expression of these small molecules actively regulates cell traffic and tissue localization of effector cells and, additionally, has direct immunological effects.

Từ khóa


Tài liệu tham khảo

10.1098/rspb.1964.0002

10.1098/rspb.1964.0001

10.1073/pnas.84.24.9233

Lindley IJD, 1993, Nomenclature announcement – the chemokines, Immunol Today, 14, 24

10.1016/S1074-7613(00)80165-X

Murphy PM, 2000, International union of pharmacology. XXII. Nomenclature for chemokine receptors, Pharmacol Rev, 52, 145

10.1016/S1074-7613(00)00074-1

10.1126/science.279.5349.381

10.1016/S0092-8674(00)80059-8

10.1084/jem.192.11.1545

10.1016/0092-8674(94)90337-9

10.1016/S0065-308X(08)60022-6

10.1002/eji.1830260410

10.1084/jem.191.12.2121

10.1016/S1074-7613(00)80460-4

10.1016/S0020-7519(97)00169-0

10.1128/IAI.67.6.3155-3159.1999

10.1007/0-306-46831-X_14

10.1016/0167-5699(93)90138-B

10.1146/annurev.immunol.16.1.495

10.1084/jem.188.8.1547

Squires KE, 1989, Experimental visceral leishmaniasis: role of endogenous IFN‐gamma in host defense and tissue granulomatous response, J Immunol, 143, 4244, 10.4049/jimmunol.143.12.4244

Liew FY, 1990, Tumour necrosis factor (TNF‐alpha) in leishmaniasis. II. TNF‐alpha‐induced macrophage leishmanicidal activity is mediated by nitric oxide from 1‐arginine, Immunology, 71, 556

Liew FY, 1990, Tumor necrosis factor‐alpha synergizes with IFN‐gamma in mediating killing of Leishmania major through the induction of nitric oxide, J Immunol, 145, 4306, 10.4049/jimmunol.145.12.4306

10.1016/S0020-7519(00)00136-3

10.1093/infdis/173.3.699

10.1111/j.1365-2249.1993.tb05931.x

10.1128/IAI.62.3.837-842.1994

10.1016/0035-9203(72)90306-9

10.1016/S0020-7519(01)00190-4

10.1002/1521-4141(200011)30:11<3111::AID-IMMU3111>3.0.CO;2-O

10.1006/expr.1996.0003

10.1016/1043-4666(89)91043-0

10.1006/expr.1996.4139

10.1189/jlb.71.2.173

10.4049/jimmunol.148.3.760

10.1182/blood.V78.4.1112.1112

Fahey TJ, 1992, Macrophage inflammatory protein 1 modulates macrophage function, J Immunol, 148, 2764, 10.4049/jimmunol.148.9.2764

Penton‐Rol G, 1998, Selective inhibition of expression of the chemokine receptor CCR2 in human monocytes by IFN‐gamma, J Immunol, 160, 3869, 10.4049/jimmunol.160.8.3869

10.1111/j.1574-695X.1996.tb00268.x

10.1128/JVI.72.1.830-836.1998

10.1182/blood.V94.3.875.415k28_875_883

Schweickart VL, 2001, CCR11 is a functional receptor for the monocyte chemoaattractant protein family of chemokines, J Biol Chem, 276, 856

10.1002/1521-4141(200201)32:1<231::AID-IMMU231>3.0.CO;2-8

10.1002/jlb.61.3.246

10.4049/jimmunol.166.2.996

10.1084/jem.187.6.875

10.1172/JCI13543

10.1038/84219

10.1159/000053827

10.1038/84298

10.1016/S0952-7915(01)00308-9

10.1084/jem.192.2.205

Thông tin
Thông tin xuất bản

Parasite Immunology

Tập 24 Số 6

295-301

Thông tin tác giả